Acute Myeloid Leukemia (AML)

Oncology·MeSH: Leukemia, Myeloid, Acute

Prevalence

6.0 / 100K

Incidence

4.3 / 100K/yr

31 drugs in development·26 companies·16 clinical trials

Drug Pipeline by Phase

Approved(5)

Drug	Company
daurismo	PFIZER INC (PFE)
komzifti	Kura Oncology, Inc. (KURA)
nypozi	GT Biopharma, Inc. (GTBP)
rezlidhia	RIGEL PHARMACEUTICALS INC (RIGL)
venetoclax	DR REDDYS LABORATORIES LTD (RDY)

Phase 3(2)

Drug	Company
pevonedistat	TAKEDA PHARMACEUTICAL CO LTD (TKPHF)
pevonedistat	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)

Phase 2(7)

Drug	Company
acr-6840	Acrivon Therapeutics, Inc. (ACRV)
BP1001	BIO-PATH HOLDINGS, INC. (BPTH)
Luveltamab tazevibulin	SUTRO BIOPHARMA, INC. (STRO)
nexi-001	NexImmune, Inc. (NEXI)
pivekimab sunirine	ImmunoGen, Inc. (IMGN)
rtx-240	Rubius Therapeutics, Inc. (RUBY)
tamibarotene	Syros Pharmaceuticals, Inc. (SYRS)

Phase 1(7)

Drug	Company
ACLX-002	Arcellx, Inc. (ACLX)
Alvocidib	AbbVie Inc. (ABBV)
cb-5339	CASI Pharmaceuticals, Inc (DE) (CASI)
CLN-049	Cullinan Therapeutics, Inc. (CGEM)
Gilteritinib	AbbVie Inc. (ABBV)
voruciclib	Lite Strategy, Inc. (LITS)
Vyxeos liposomal	Jazz Pharmaceuticals plc (JAZZ)

Preclinical(6)

Drug	Company
ACLX-004	Arcellx, Inc. (ACLX)
gb3226	Damora Therapeutics, Inc. (DMRA)
oncotox-aml	OMEROS CORP (OMER)
rasp-101	ACTAVIA LIFE SCIENCES, INC. (RASP)
rasp-201	ACTAVIA LIFE SCIENCES, INC. (RASP)
rasp-301	ACTAVIA LIFE SCIENCES, INC. (RASP)

Unknown(1)

Drug	Company
BST-236	Ayala Pharmaceuticals, Inc. (ADXS)

Clinical(1)

Drug	Company
ast-vac1	ASTERIAS BIOTHERAPEUTICS, INC. (AST)

Phase 2/Phase 3(1)

Drug	Company
Actimab-A	Actinium Pharmaceuticals, Inc. (ATNM)

Phase 4(1)

Drug	Company
Venetoclax	AbbVie Inc. (ABBV)

BioSniper tracks 31 drugs in development for Acute Myeloid Leukemia (AML) across 26 companies.

There are 16 clinical trials targeting Acute Myeloid Leukemia (AML) tracked by BioSniper.

The estimated prevalence of Acute Myeloid Leukemia (AML) is approximately 6.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.